The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zismirt orotab 30 mg Orodispersible Tablets

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/059/003

Main Information

Trade NameZismirt orotab 30 mg Orodispersible Tablets
Active SubstancesMirtazapine
Dosage FormOrodispersible tablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/059/003

Group Information

ATC CodeN06AX Other antidepressants
N06AX11 mirtazapine


License statusAuthorised
Licence Issued25/01/2008
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0061-033-015
Interchangeable List DocumentPDF of Interchangeable List
« Back